James Berger - Hofseth Biocare Chief Officer

All Insiders . Norway . 
Stock . Hofseth Biocare ASA . Stakeholders . Insider . James Berger
HBC Stock  NOK 1.22  0.08  6.15%   

Insider

James Berger is Chief Officer of Hofseth Biocare ASA
Phone47 73 10 22 00
Webhttps://www.hofsethbiocare.no

Hofseth Biocare Management Efficiency

The company has return on total asset (ROA) of (0.1942) % which means that it has lost $0.1942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9478) %, meaning that it generated substantial loss on money invested by shareholders. Hofseth Biocare's management efficiency ratios could be used to measure how well Hofseth Biocare manages its routine affairs as well as how well it operates its assets and liabilities.
Hofseth Biocare ASA has accumulated 123.31 M in total debt with debt to equity ratio (D/E) of 188.2, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Hofseth Biocare ASA has a current ratio of 1.09, suggesting that it is not liquid enough and may have problems paying out its financial obligations in time and when they become due. Debt can assist Hofseth Biocare until it has trouble settling it off, either with new capital or with free cash flow. So, Hofseth Biocare's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hofseth Biocare ASA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hofseth to invest in growth at high rates of return. When we think about Hofseth Biocare's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Niclas HugossonCarasent ASA
N/A
Henrik BadinVow ASA
53
Zygimantas DirseKitron ASA
43
Lars NilssonKitron ASA
59
Advocate SchultzCarasent ASA
N/A
Akil JacksonBergenbio ASA
N/A
Patricia KellyPhotocure
N/A
Nigel MScBergenbio ASA
N/A
Kari MDPhotocure
N/A
Kristoffer AsklovKitron ASA
46
Tolv HillestadPhotocure
N/A
Martin OlinBergenbio ASA
54
Chris DamvakarisCarasent ASA
N/A
Henning MohnVow ASA
N/A
Gayle MBABergenbio ASA
68
Cristina MDBergenbio ASA
N/A
James BarnesBergenbio ASA
N/A
Magnus LindsethKitron ASA
46
Stian HaugenKitron ASA
47
Mindaugas SestokasKitron ASA
52
David MoskowitzPhotocure
N/A
Hofseth BioCare ASA, a biotech company, offers value added biomarine ingredients and finished products for human consumption and pet in Norway. The company was founded in 2000 and is headquartered in lesund, Norway. HOFSETH BIOCARE operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 44 people. Hofseth Biocare ASA (HBC) is traded on Oslo Stock Exchange in Norway and employs 9 people.

Management Performance

Return On Equity-0.95
Return On Asset-0.19

Hofseth Biocare ASA Leadership Team

Elected by the shareholders, the Hofseth Biocare's board of directors comprises two types of representatives: Hofseth Biocare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hofseth. The board's role is to monitor Hofseth Biocare's management team and ensure that shareholders' interests are well served. Hofseth Biocare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hofseth Biocare's outside directors are responsible for providing unbiased perspectives on the board's policies.
Angelika Florvaag, Chief Officer
Olav Flaten, Exec
Tanja Schaffer, EVP GmbH
Jon Odegard, Chief Officer
Matt Mixter, Managing America
Bomi Framroze, Chief Officer
James Berger, Chief Officer
Karl Slotsvik, Chief Officer
Crawford Currie, Head Director

Hofseth Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hofseth Biocare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.95
Return On Asset-0.19
Profit Margin(1.14) %
Operating Margin(1.07) %
Current Valuation1.03 B
Shares Outstanding395.08 M
Shares Owned By Insiders52.50 %
Shares Owned By Institutions20.43 %
Price To Earning(4.13) X
Price To Book5.19 X

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Other Information on Investing in Hofseth Stock

Hofseth Biocare financial ratios help investors to determine whether Hofseth Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hofseth with respect to the benefits of owning Hofseth Biocare security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY